The Impact of Tacrolimus on Vascular Endothelial Growth Factor in Experimental Corneal Neovascularization

REFERENCES

• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27–31.
   PubMed Web of Science ®Google Scholar
• Chang JH, Gabison EE, Kato T, et al. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12:242–249.
   PubMed Web of Science ®Google Scholar
• Cursiefen C, Kuchle M, Naumann GO. Angiogenesis in corneal diseases: Histopathologic evaluation of 254 human corneal buttons with neovascularization. Cornea. 1998;17:611–613.
   PubMed Web of Science ®Google Scholar
• Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480–1487.
   PubMed Web of Science ®Google Scholar
• Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci. 1998;39:18–22.
   PubMed Web of Science ®Google Scholar
• Phillips GD, Stone AM, Jones BD, et al. Vascular endothelial growth factor (rhVEGF165) stimulates direct angiogenesis in the rabbit cornea. In Vivo. 1994;8:961–965.
   PubMedGoogle Scholar
• Gan L, Fagerholm P, Palmblad J. Vascular endothelium growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand. 2004;82:557–563.
   PubMedGoogle Scholar
• Edelman JL, Castro MR, Wen Y. Correlation of VEGF expression by leukocytes with the growth and regression of blood vessels in the rat cornea. Invest Ophthalmol Vis Sci. 1999;40:1112–1123.
   PubMed Web of Science ®Google Scholar
• Kim B, Tang Q, Biswas PS, et al. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes. Am J Pathol. 2004;165:2177–2185.
   PubMed Web of Science ®Google Scholar
• Binetruy-Tournaire R, Demangel C, Malavaud B, et al. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J. 2000;19:1525–1533.
   PubMed Web of Science ®Google Scholar
• Kvanta A. Ocular angiogenesis: The role of growth factors. Acta Ophthalmol Scand. 2006;84:282–288.
   PubMedGoogle Scholar
• Knoll GA, Bell RC. Tacrolimus versus cyclosporine for immunosuppression in renal transplantation: Meta-analysis of randomized trials. BMJ. 1999;318:1104–1107.
   PubMed Web of Science ®Google Scholar
• Cespo-Leiro MG. Tacrolimus in heart transplantation. Transplant Proc. 2003;35:1981–1983.
   PubMedGoogle Scholar
• Bhorade SM, Jordan A, Villanueva L, et al. Comparison of three tacrolimus-based immunosuppressive regimens in lung transplantation. Am J Transplant. 2003;3:1570–1575.
   PubMedGoogle Scholar
• Reis A, Reinhard T, Sundmacher R, Braunstein S, Godehardt E. A comparative investigation of FK506 and cyclosporin A in murine corneal transplantation. Graefes Arch Clin Exp Ophthalmol. 1998;236:785–789.
   PubMedGoogle Scholar
• Sloper CM, Powell RJ, Dua HS. Tacrolimus in the management of high risk corneal and limbal grafts. Ophthalmology. 2001;108:1838–1844.
   PubMed Web of Science ®Google Scholar
• Cho ML, Cho CS, Min SY, et al. Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts. Arthritis Rheum. 2002;46:1202–1209.
   PubMed Web of Science ®Google Scholar
• Mahoney JM, Waterbury LD. Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea. Curr Eye Res. 1985;4:531–535.
   PubMed Web of Science ®Google Scholar
• Manzano RP, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularization by bevacizumab (Avastin). Br J Ophthalmol. 2007;91:804–807.
   PubMed Web of Science ®Google Scholar
• Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000;41:2514–2522.
   PubMed Web of Science ®Google Scholar
• Kvanta A. Ocular angiogenesis: the role of growth factors. Acta Ophthalmol Scand. 2006;84:282–288.
   PubMedGoogle Scholar
• Cursiefen C, Rummelt C, Kuchle M. Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization. Cornea. 2000;19,526–533.
   PubMed Web of Science ®Google Scholar
• Kim I, Ryan AM, Rohan R, et al. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci. 1999;40:2115–2121.
   PubMed Web of Science ®Google Scholar
• Miyata S, Ohkuba Y, Mutoh S. A review of the action of tacrolimus (FK506) on experimental models of rheumatoid arthritis. Inflamm Res. 2005;54:1–9.
   PubMed Web of Science ®Google Scholar
• Morikawa K, Oseko F, Morikowa S. The distinct effects of FK506 on the activation, proliferation, and differentiation of human B lymphocytes. Transplantation. 1992;54:1025–1030.
   PubMedGoogle Scholar
• Walgenbach KJ, Kalff JC, Sonmez-Alpan E, et al. Upregulation of basic fibroblast growth factor during chronic rejection of rat intestinal allografts and its downregulation by FK 506. Transplant Proc. 1998;30:2587.
   PubMedGoogle Scholar
• Lopez-Ilasaca M, Schiene C, Küllertz G, et al. Effects of FK506-binding protein 12 and FK506 on autophosphorylation of epidermal growth factor receptor. J Biol Chem. 1998;273:9430–9434.
   PubMedGoogle Scholar
• Sengoku T, Kishi S, Sakuma S, et al. FK506 inhibition of histamine release and cytokine production by mast cells and basophils. Int J Immunopharmacol. 2000;22:189–201.
   PubMedGoogle Scholar
• Savikko J, Taskinen E, Von Willebrand E. Tacrolimus inhibits platelet-derived growth factor ligand and receptor induction as well as rejection changes in rat renal allografts during long-term follow-up. Transplant Proc. 2002;34:1382.
   PubMedGoogle Scholar
• Sasakawa T, Sasakawa Y, Ohkuba Y, et al. FK506 inhibits prostaglandin E2 production from synovial cells by suppressing peripheral blood mononuclear cells. Int Immunopharmacol. 2005;5:1291–1297.
   PubMedGoogle Scholar
• Migita K, Maeda Y, Abiru S, et al. Immunosuppressant FK506 inhibits matrix metalloproteinase-9 induction in TNF-alpha-stimulated human hepatic stellate cells. Life Sci. 2006;78:2510–2515.
   PubMedGoogle Scholar
• Migita K, Miyashita T, Maeda Y, et al. FK506 suppresses the stimulation of matrix metalloproteinase 13 synthesis by interleukin-1beta in rheumatoid synovial fibroblasts. Immunol Lett. 2005;98:194–199.
   PubMedGoogle Scholar
• Sakuma S, Kato Y, Nishigaki F, et al. FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells. Br J Pharmacol. 2000;130:1655–1663.
   PubMed Web of Science ®Google Scholar
• Sakuma S, Kato Y, Nishigaki F, et al. Effects of FK506 and other immunosuppressive anti-rheumatic agents on T cell activation mediated IL-6 and IgM production in vitro. Int Immunopharmacol. 2001;1:749–757.
   PubMed Web of Science ®Google Scholar
• Kong X, Lin Z, Caro J. Immunophilin-ligands FK506 and CsA inhibit HIF1a expression by a VHL- and ubiquitin-independent mechanism. FEBS Lett. 2006;580:6182–6186.
   PubMedGoogle Scholar
• Lan CC, Yu HS, Wu CS, et al. FK506 inhibits tumour necrosis factor-alpha secretion in human keratinocytes via regulation of nuclear factor-kappa B. Br J Dermatol. 2005;153:725–732.
   PubMed Web of Science ®Google Scholar
• Kohyama T, Takizawa H, Kawasaki S, et al. A potent immunosuppressant FK506 inhibits IL-8 expression in human eosinophils. Mol Cell Biol Res Commun. 1999;1:72–77.
   PubMedGoogle Scholar
• Drixler TA, Voest EE, van Vroonhoven TJ, et al. Angiogenesis and surgery: From mice to man. Eur J Surg. 2000;166:435–446.
   PubMedGoogle Scholar
• Honma Y, Nishida K, Sotozono C, et al. Effect of transforming growth factor-beta1 and -beta2 on in vitro rabbit corneal epithelial cell proliferation promoted by epidermal growth factor, keratinocyte growth factor, or hepatocyte growth factor. Exp Eye Res. 1997;65:391–396.
   PubMed Web of Science ®Google Scholar
• Freeman MR, Schneck FX, Gagnon ML, et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: A potential role for T cells in angiogenesis. Cancer Res. 1995;55:4140–4145.
   PubMed Web of Science ®Google Scholar
• Gunsilius E, Petzer A, Stockhammer G, et al. Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology. 2000;58:169–174.
   PubMed Web of Science ®Google Scholar
• Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004;14:433–439.
   PubMed Web of Science ®Google Scholar
• Costa C, Incio J, Soares R. Angiogenesis and chronic inflammation: Cause or consequence? Angiogenesis. 2007;10:149–166.
   PubMedGoogle Scholar